Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rucaparib

rucaparib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rucaparib

20 trials tracked of rucaparib: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 423 citations.

20Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 12 Phase 1 3 Other / NA 1
  1. Phase 3 A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Completed · 423 cited
  2. Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Completed · 143 cited
  3. Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Completed · 130 cited
  4. Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Completed
  5. Phase 2 PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers Completed
  6. Phase 2 Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Completed
Show 14 more trials
  1. Phase 2 Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium Completed
  2. Phase 2 A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Completed
  3. Phase 2 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer Completed
  4. Phase 2 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) Completed
  5. Phase 2 Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Completed
  6. Phase 2 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations Completed
  7. Phase 2 The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) Completed
  8. Phase 2 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer Completed
  9. Phase 2 Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Completed
  10. Phase 2 An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer Completed
  11. Phase 1 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Completed
  12. Phase 1 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy Completed
  13. Phase 1 Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) Completed
  14. N/A Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study Completed

Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer
Oncology Meta-analysis
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer PARP Inhibitors Show Improved Survival for Advanced Ovarian Cancer
This network meta-analysis of randomized trials evaluates PARP inhibitors for advanced ovarian cancer. The analysis indicates that olaparib,…
New data shows PARP inhibitors like olaparib and niraparib may improve survival for both younger and older patients with advanced ovarian ca…
Frontiers Jul 9, 2026
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up
Drug Pipeline Phase II
Phase II trial of rucaparib maintenance in metastatic endometrial cancer completes follow-up Can a maintenance drug help keep advanced endometrial cancer at bay?
A phase II randomized controlled trial evaluated rucaparib maintenance versus placebo in 79 patients with metastatic/recurrent endometrial c…
A trial testing rucaparib as maintenance therapy for advanced endometrial cancer has finished, but results on whether it delays cancer growt…
CT.gov Mar 30, 2026